Dr. Mahmood Kafaii Razavi, MD

Dr. Razavi practices at Providence St. Joseph Hospital Orange in Orange, California, part of Providence Health & Services.

Dr. Razavi's NPI, 1851388607, was assigned on October 5, 2005. Dr. Razavi holds California license G66274.

Dr. Razavi's primary practice is Providence St. Joseph Hospital Orange, at 1100 West Stewart Dr, Orange, CA 92868 in Orange County. The practice phone is (714) 633-9111.

Dr. Razavi's primary practice is Providence St. Joseph Hospital Orange in Orange, California, part of Providence Health & Services. The medical group on file is Vascular & Interventional Specialists of Orange County. Dmand AI also links Dr. Razavi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Razavi practices, 2 sites in all. Vendor and product names are available with a free account.

Vascular and interventional radiology is Dr. Razavi's primary specialty in the NPI Registry, under taxonomy code 2085R0204X. Dr. Razavi is licensed in California.

CMS data shows 626 Medicare services from Dr. Razavi across 21 procedure codes in 2024, for 378 Medicare patients. Medicare paid $45,653 for them.

CMS counts 378 Medicare patients who saw Dr. Razavi in 2024. The largest group is 75 to 84, with 134 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 40% are also on Medicaid. Their average risk score is 4.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Razavi's median patient age at 70, with 54% women.

In 2024, Dr. Razavi wrote 22 Medicare Part D claims. 50% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $9,840 in total drug cost. In 2023, CMS named 27 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 69 out of 100 for Dr. Razavi for performance year 2024, reported individually. Dr. Razavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 19 procedures of leg revascularization (restoring blood flow) by Dr. Razavi, more than 79% of the clinicians it reports for that procedure.

Dmand AI links 51 papers to Dr. Razavi, published from 2011 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Vascular Patency, Endovascular Procedures and Iliac Vein. Dr. Razavi has published most often in J Vasc Interv Radiol. Dr. Razavi's most frequent co-authors are Michael Ritt Jaff, DO, Suresh Vedantham, MD and Anthony J. Comerota, MD.

Dmand AI links Dr. Razavi to 11 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Peripheral Arterial Disease, Peripheral Vascular Diseases and Arteriovenous Fistula. C. R. Bard sponsors the most, 5. Open Payments lists research payments to Dr. Razavi that name 4 trials.

CMS Open Payments shows 1,046 general payments to Dr. Razavi from 61 drug and device companies from 2016 to 2025. Acquisitions make up the largest share, 67% of the total. Walk Vascular, LLC paid the most, $844,854. It also lists 36 research payments totaling $59,418 from 2016 to 2025, naming 4 clinical trials.